Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Suraj B. Sable, Wen Li, Allison Kline, Sakthivel Govindaraj, Vijayakumar Velu, et al.
…granulomatous diseases. Summary Safer and shorter treatment regimens for tuberculosis (TB) are urgently needed. Host-directed therapies (HDT) are being explored to enhance antibiotic regimens and address antimicrobial resistance. To expedite the discovery of HDT candidates and th…
Dongxia Zhu, Martin R. Bryce
… contribute to the poor outcomes of conventional antibiotic regimens. So far, several types of nanodrugs including PEGylated liposomes, PEGylated quantum dots, and polymer micelles have been studied with the aim of granuloma targeting [2, 3]. However, these nanoparticles (NPs) ca…
Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, et al.
The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was 12-month tuberculosis disease free sur…
Digby F. Warner, Robin Wood
…inical M. tuberculosis infections be treated and with which regimens? In some ways, the hesitation to acknowledge subclinical infections as potentially major sources of TB transmission events might stem partially from history. Robert Koch developed his paradigmatic postulates to …
Shurygina AS, Zabolotnykh NV, Vinogradova TI, Vitovskaya ML, Dogonadze MZ, et al.
…resistant tuberculosis (TB), which renders standard therapy regimens ineffective, necessitates the development of innovative treatment approaches. Immunotherapeutic vaccines have the potential to effectively regulate the anti-TB immune response and enhance the efficacy of anti-TB…
National Institute of Allergy and Infectious Diseases (NIAID)
A5406 hypothesizes that dolutegravir (DTG) 50 mg taken twice daily will provide adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated TB. This is an open-label, single arm, phase II, multicenter PK study to investigate the …
Jason Farley, PhD, MPH, ANP-BC, Denise Evans, PhD, Norbert Ndjeka, MBChB
…ons for RR-TB treatment earlier this year endorsing 6-month regimens and calling for decentralized, patient-centered models of care closer to the patient's home. Although SA has long been a leading implementer of nurse-led models of care for TB and HIV due to large physician sho…
Jianghua Yang, Jian Sun, Wenjie Wang, Jing Ding, Yusheng Cheng, et al.
Abstract Background Duration of antituberculosis therapy (ATT) for managing female genital tuberculosis (FGTB) is controversial with the intermittent regimen no more advocated. We therefore conducted a prospective, real-world research to compare 6 months and 9 months of ATT. Meth…
Jian Sun, Wenjie Wang, Jing Ding, Yusheng Cheng, Yunfeng Zhou, et al.
Abstract Background Duration of antituberculosis therapy (ATT) for managing female genital tuberculosis (FGTB) is controversial with the intermittent regimen no more advocated. We therefore conducted a prospective, real-world research to compare 6 months and 9 months of ATT. Meth…
Shiv Shankar Tyagi, Prema Balusamy
Tuberculosis is an infectious disease caused by mycobacterium tuberculosis. It affects the lungs and other organs. The disease is spread through the air when people who are sick with pulmonary TB expel the bacteria. Most productive age group is affected by tuberculosis. In India,…
Jian Sun, Wenjie Wang, Jing Ding, Yusheng Cheng, Yunfeng Zhou, et al.
Abstract Background Duration of antituberculosis therapy (ATT) for managing female genital tuberculosis (FGTB) is controversial with the intermittent regimen no more advocated. We therefore conducted a prospective, real-world research to compare 6 months and 9 months of ATT. Meth…
Morounfolu Olugbosi, MD
The goal of this clinical trial is to evaluate 3 dose levels of TBAJ876 for 8 weeks in combination with pretomanid and linezolid, compared to 8 weeks of Isoniazid, rifampicin, pyrazinamide and ethambutol (2HRZE), in adult participants with newly diagnosed, smear-positive, pulmona…
Rajendra Prasad, Abhijeet Singh, Nikhil Gupta
Drug-susceptible tuberculosis (DS-TB) requires treatment with first-line drugs (FLDs) whereas drug-resistant TB (DR-TB) are treated with combination of second-line drugs (SLDs) and fewer FLDs. Adverse drug reactions (ADRs) to these drugs are quite evident as they are being used f…
Ismaheel O. Lawal, Bernard Fourie, Matsontso Mathebula, Ingrid Moagi, Thabo Lengana, et al.
296 Background: FDG PET/CT imaging at the completion of anti-tuberculosis therapy (ATT) may show residual metabolically activity (RMA) in patients considered cured at end of treatment (EOT) based on current standard of care diagnostic definitions. The significance of RMA as a ris…
Kruti Panchal, Trupti M Solu
India is among the countries that carry the highest burden for tuberculosis. Antitubercular drugs are frequently associated with ocular toxicity. Among ATT, ethambutol is the most commonly implicated drug causing optic neuropathy. For assessing spectrum of ATT induced ocular toxi…
Simon C Mendelsohn, Bruno B Andrade, Mariana Araújo-Pereira, Gustavo C Amorim, Mzwandile Erasmus, et al.
…ded trials to individualise tuberculosis therapy-shortening regimens for early responders and intensifying care for high-risk patients.
Wang T, Quijada D, Ahmedna T, Castillo JR, Naji NS, et al.
Tuberculosis (TB) remains among the leading infectious causes of death. Due to the limited number of antimicrobials in the TB drug discovery pipeline, interest has developed in host-directed approaches to improve TB treatment outcomes. C-C motif chemokine-like receptor 2 (CCRL2) …
Suresh S, Begum RF, Singh SA, Vellapandian C
Drug repurposing is an ongoing and clever strategy that is being developed to eradicate tuberculosis amid challenges, of which one of the major challenges is the resistance developed towards antibiotics used in standard directly observed treatment, short-course regimen. Surpassin…
Kerkhoff AD, Zucker J, Havlir DV
Several novel antituberculosis agents, including long-acting injectable agents in mouse models, have shown promise in preclinical and early clinical studies. This encouraging news is offset by the failures of a tuberculosis (TB) vaccine to prevent disease recurrence and a 3-month…
Kivrane A, Ulanova V, Grinberga S, Sevostjanovs E, Viksna A, et al.
Background: Serum C-reactive protein (CRP) levels vary depending on radiological and bacteriological findings at the time of tuberculosis (TB) diagnosis. However, the utility of this biomarker in monitoring response to anti-TB treatment and identifying patients at risk of treatme…
Mitton-Fry MJ, Cummings JE, Lu Y, Armenia JF, Byl JAW, et al.
…er an alternative to fluoroquinolones in future therapeutic regimens.
Tadesse AW, Mganga A, Dube TN, Alacapa J, van Kalmthout K, et al.
Introduction Digital adherence technologies (DATs) can offer alternative approaches to support tuberculosis treatment medication adherence. Evidence on their feasibility and acceptability in high TB burden settings is limited. We conducted a cross-sectional survey among adults wi…
Santos F, Pires D, Anes E, Duarte ARC
…ls related, for example, to the administration of prolonged regimens of multiple drugs, different severe adverse effects, low compliance of the patient to treatment and the development of drug resistance. During this study, it was possible to assess the physicochemical stability …
Huang CK, Yu MC, Hung CS, Lin JC
…pic-coupled bioinformatic approach to manage PZA-containing regimens for patients with MTB.
Muzanyi G, Mafigiri DK, Salata R, Joloba M, Mukonzo J, et al.
Background The current six months regimen for drug-susceptible tuberculosis (TB) is long, complex, and requires adherence monitoring. TB hair drug level assay is one innovative approach to monitor TB treatment adherence however, its acceptability in the context of African multi-c…